姜黄素治疗口腔黏膜下纤维性变有效性的Meta分析

doi:10.7518/hxkq.2021.02.011

华西口腔医学杂志 ›› 2021, Vol. 39 ›› Issue (2): 195-202.doi: 10.7518/hxkq.2021.02.011

姜黄素治疗口腔黏膜下纤维性变有效性的Meta分析

郭锦材¹(), 谢辉¹(), 吴昊¹, 童铁军²

^1.长沙市口腔医院，长沙 410006
^2.香港浸会大学数学系，香港 999077

收稿日期:2020-07-17 修回日期:2020-11-14 出版日期:2021-04-01 发布日期:2021-04-09
通讯作者: 谢辉 E-mail:540009728@qq.com;kqyyxh1@126.com
作者简介:郭锦材，主管药师，硕士，E-mail：540009728@qq.com
基金资助:
湖南省保健专项资金科研课题(B2020-07);湖南省医学会医学科研基金临床药学项目(HMA202001012);湖南省临床医疗技术创新引导项目(2020SK53206);长沙市自然科学基金项目(kq2014019);长沙市卫生计生委科研计划课题项目(201809);湖南省重点研发计划项目(2020SK2137)

Efficacy of curcumin in the treatment of oral submucous fibrosis: a Meta-analysis

Guo Jincai¹(), Xie Hui¹(), Wu Hao¹, Tong Tiejun²

^1.Changsha Stomatological Hospital, Changsha 410006, China
^2.Dept. of Mathematics, Hong Kong Baptist University, Hongkong 999077, China

Received:2020-07-17 Revised:2020-11-14 Online:2021-04-01 Published:2021-04-09
Contact: Xie Hui E-mail:540009728@qq.com;kqyyxh1@126.com
Supported by:
Health Care Special Fund Research Project of Hunan Province(B2020-07);Clinical Pharmacy Project of Medical Research Fund of Hunan Medical Association(HMA202001012);Clinical Medical Technology Innovation Guiding Project of Hunan Province(2020SK53206);Natural Science Foundation of Changsha(kq2014019);Research Project Funding of Changsha Municipal Health and Family Planning Commission(201809);Key R & D Project of Hunan Province(2020SK2137)

摘要/Abstract

摘要： 目的

系统性地评价姜黄素治疗口腔黏膜下纤维性变的有效性。

方法

检索Web of Science、PubMed、EBSCO、The Cochrane Library、中国知网、万方和维普7个数据库，检索时限为从建库到2019年6月30日，搜集姜黄素治疗口腔黏膜下纤维性变的随机对照试验，筛选文献，提取数据，用RevMan 5.3软件进行Meta分析。

结果

纳入6个随机对照试验，共350名患者。Meta分析结果显示，姜黄素改善口腔黏膜下纤维性变的最大张口度和烧灼感症状疗效优于安慰剂。改善张口度方面，治疗1个月后，姜黄素疗效不如番茄红素等控制组；但治疗2个月、3个月和6个月后姜黄素组和控制组疗效相似，差异无统计学意义。烧灼感改善方面，治疗3个月后，姜黄素的疗效比控制组更好，且差异有统计学意义；治疗1个月、2个月和6个月后，姜黄素组和控制组的疗效差异无统计学意义。

结论

当前证据显示，姜黄素可以有效地改善口腔黏膜下纤维性变患者的最大张口度和烧灼感等症状。由于纳入研究数量有限和质量不高，上述结论尚需更多高质量研究予以验证。

关键词: 口腔黏膜下纤维性变, 姜黄素, Meta分析, 循证医学

Abstract: Objective

This study was performed to review the efficacy of curcumin in the treatment of oral submucous fibrosis systematically.

Methods

We searched seven databases, including Web of Science, PubMed, EBSCO, The Cochrane Library, CNKI, WanFang Data, and VIP, to obtain randomized controlled trials related to the treatment of oral submucous fibrosis by curcumin. Each database was searched from inception to 30 June 2019. RevMan 5.3 software was used for the meta-analysis.

Results

Six randomized controlled trials involving 350 patients were included in this study. Meta-analysis showed that curcumin can increase the maximal mouth opening and improve burning sensation compared with placebo treatment. Curcumin was not as effective as the controls in achieving maximal mouth opening after 1 month of treatment. However, no statistically significant difference was observed between the treatments from 2 months to 6 months. Curcumin significantly improved burning sensation compared with the controls after 3 months of treatment. No statistically significant diffe-rence in burning sensation was observed between the curcumin and control groups after 1, 2, and 6 months of treatment.

Conclusion

The current evidence shows that curcumin is an effective treatment for improving maximal mouth opening and burning sensation in patients with oral submucous fibrosis. Given the limited number and low quality of the included studies, however, more high-quality studies are needed to verify these findings.

Key words: oral submucous fibrosis, curcumin, Meta-analysis, evidence-based medicine

中图分类号:

R 781.5

郭锦材, 谢辉, 吴昊, 童铁军. 姜黄素治疗口腔黏膜下纤维性变有效性的Meta分析[J]. 华西口腔医学杂志, 2021, 39(2): 195-202.

Guo Jincai, Xie Hui, Wu Hao, Tong Tiejun. Efficacy of curcumin in the treatment of oral submucous fibrosis: a Meta-analysis[J]. West China Journal of Stomatology, 2021, 39(2): 195-202.

图/表 8

表 1

图 1

表 2

表 3

图 2

图 3

图 4

图 5

参考文献 36

1	Liu J, Chen F, Wei Z, et al. Evaluating the efficacy of pentoxifylline in the treatment of oral submucous fibrosis: a meta-analysis[J]. Oral Dis, 2018, 24(5): 706-716.
2	Al-Maweri SA, Ashraf S, Lingam AS, et al. Aloe vera in treatment of oral submucous fibrosis: a systematic review and meta-analysis[J]. J Oral Pathol Med, 2019, 48(2): 99-107.
3	Trivedy C, Baldwin D, Warnakulasuriya S, et al. Copper content in Areca catechu (betel nut) products and oral submucous fibrosis[J]. Lancet, 1997, 349(9063): 1447.
4	Ray JG, Chatterjee R, Chaudhuri K. Oral submucous fibrosis: a global challenge. Rising incidence, risk factors, management, and research priorities[J]. Periodontol 2000, 2019, 80(1): 200-212.
5	Kondaiah P, Pant I, Khan I. Molecular pathways regula-ted by areca nut in the etiopathogenesis of oral submucous fibrosis[J]. Periodontol 2000, 2019, 80(1): 213-224.
6	Zhang SS, Li WH, Gao YJ, et al. Betel-quid and oral submucous fibrosis: a cross-sectional study in Hunan Province, China[J]. J Oral Pathol Med, 2012, 41(10): 748-754.
7	唐杰清, 翦象福, 高明亮, 等. 中国湖南湘潭口腔黏膜下纤维性变的流行病学研究[J]. 中国医师杂志, 2015, 17(9): 1290-1295.
	Tang JQ, Jian XF, Gao ML, et al. Epidemiological survey of oral submucous fibrosis in Xiangtan City, Hunan Province, China[J]. J Chin Physic, 2015, 17(9): 1290-1295.
8	Yang SF, Wang YH, Su NY, et al. Changes in prevalence of precancerous oral submucous fibrosis from 1996 to 2013 in Taiwan: a nationwide population-based retrospective study[J]. J Formos Med Assoc, 2018, 117(2): 147-152.
9	Pindborg JJ, Mehta FS, Gupta PC, et al. Prevalence of oral submucous fibrosis among 50, 915 Indian villagers[J]. Br J Cancer, 1968, 22(4): 646-654.
10	Kumar S, Debnath N, Ismail MB, et al. Prevalence and risk factors for oral potentially malignant disorders in Indian population[J]. Adv Prev Med, 2015, 2015: 208519.
11	郭锦材, 谢辉. 中医药治疗口腔黏膜下纤维化的临床研究进展[J]. 口腔医学研究, 2019, 35(5): 423-426.
	Guo JC, Xie H. Research progress of traditional Chinese medicine in treatment of oral submucous fibrosis[J]. J Oral Sci Res, 2019, 35(5): 423-426.
12	Chole RH, Gondivkar SM, Gadbail AR, et al. Review of drug treatment of oral submucous fibrosis[J]. Oral Oncol, 2012, 48(5): 393-398.
13	刘锦丽, 陈方曼, 江潞. 口腔黏膜下纤维性变的药物治疗进展[J]. 国际口腔医学杂志, 2017, 44(3): 325-331.
	Liu JL, Chen FM, Jiang L. Drug management of oral submucous fibrosis[J]. Int J Stomatol, 2017, 44(3): 325-331.
14	翦新春, 郑廉, 朱蓉, 等. 曲安奈德和丹参酮注射液治疗口腔黏膜下纤维化的效果评价[J]. 中华口腔医学杂志, 2017, 52(1): 16-21.
	Jian XC, Zheng L, Zhu R, et al. Clinical effectiveness of salvianolic acid B and triamcinolone acetonide in treatment of oral submucous fibrosis[J]. Chin J Stomatol, 2017, 52(1): 16-21.
15	郭锦材, 谢辉. 天然药物提取物治疗口腔黏膜下纤维性变的临床研究进展[J]. 临床口腔医学杂志, 2018, 34(11): 692-695.
	Guo JC, Xie H. The clinical research progress of natural drug extracts in the treatment of oral submucous fibrosis[J]. J Clin Stomatol, 2018, 34(11): 692-695.
16	Piyush P, Mahajan A, Singh K, et al. Comparison of the-rapeutic response of lycopene and curcumin in oral submucous fibrosis: a randomized controlled trial[J]. Oral Dis, 2019, 25(1): 73-79.
17	Saran G, Umapathy D, Misra N, et al. A comparative study to evaluate the efficacy of lycopene and curcumin in oral submucous fibrosis patients: a randomized clinical trial[J]. Indian J Dent Res, 2018, 29(3): 303-312.
18	Ara SA, Mudda J, Lingappa A, et al. Efficacy of curcu-min in oral submucous fibrosis—a randomized controlled clinical trial[J]. Int J Pharm Sci Res, 2018, 9(12): 5277-5286.
19	Kopuri RKC, Chakravarthy C, Sunder S, et al. A comparative study of the clinical efficacy of lycopene and curcumin in the treatment of oral submucous fibrosis using ultrasonography[J]. J Int Oral Health, 2016, 8(6): 687-691.
20	Hazarey VK, Sakrikar AR, Ganvir SM. Efficacy of curcumin in the treatment for oral submucous fibrosis—a randomized clinical trial[J]. J Oral Maxillofac Pathol, 2015, 19(2): 145-152.
21	Yadav M, Aravinda K, Saxena VS, et al. Comparison of curcumin with intralesional steroid injections in oral submucous fibrosis—a randomized, open-label interventio-nal study[J]. J Oral Biol Craniofac Res, 2014, 4(3): 169-173.
22	夏丽, 李冰. 姜黄素在抗口腔黏膜下纤维化中的作用研究进展[J]. 解放军医学杂志, 2019, 44(4): 357-360.
	Xia L, Li B. Research progress of curcumin in anti-oral submucous fibrosis[J]. Med J Chin PLA, 2019, 44(4): 357-360.
23	Al-Maweri SA. Efficacy of curcumin for management of oral submucous fibrosis: a systematic review of randomized clinical trials[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2019, 127(4): 300-308.
24	Mirzaei H, Shakeri A, Rashidi B, et al. Phytosomal curcumin: a review of pharmacokinetic, experimental and clinical studies[J]. Biomedecine Pharmacother, 2017, 85: 102-112.
25	Ara SA, Mudda JA, Lingappa A, et al. Research on curcumin: a meta-analysis of potentially malignant disorders[J]. J Cancer Res Ther, 2016, 12(1): 175-181.
26	Shih YH, Wang TH, Shieh TM, et al. Oral submucous fibrosis: a review on etiopathogenesis, diagnosis, and the-rapy[J]. Int J Mol Sci, 2019, 20(12): E2940.
27	Arakeri G, Rai KK, Hunasgi S, et al. Oral submucous fibrosis: an update on current theories of pathogenesis[J]. J Oral Pathol Med, 2017, 46(6): 406-412.
28	Zhang SS, Gong ZJ, Li WH, et al. Antifibrotic effect of curcumin in TGF-β 1-induced myofibroblasts from human oral mucosa[J]. Asian Pac J Cancer Prev, 2012, 13(1): 289-294.
29	Deng YT, Chen HM, Cheng SJ, et al. Arecoline-stimula-ted connective tissue growth factor production in human buccal mucosal fibroblasts: modulation by curcumin[J]. Oral Oncol, 2009, 45(9): e99-e105.
30	Rai B, Kaur J, Jacobs R, et al. Possible action mechanism for curcumin in pre-cancerous lesions based on serum and salivary markers of oxidative stress[J]. J Oral Sci, 2010, 52(2): 251-256.
31	Gupta S, Ghosh S, Gupta S, et al. Effect of curcu-min on the expression of p53, transforming growth factor-β, and inducible nitric oxide synthase in oral submucous fibrosis: a pilot study[J]. J Investig Clin Dent, 2017, 8(4). doi: 10.1111/jicd.12252.
32	Chang MC, Chen YJ, Chang HH, et al. Areca nut components affect COX-2, cyclin B1/cdc25C and keratin expression, PGE2 production in keratinocyte is related to reactive oxygen species, CYP1A1, Src, EGFR and Ras signaling[J]. PLoS One, 2014, 9(7): e101959.
33	Farhood B, Mortezaee K, Goradel NH, et al. Curcumin as an anti-inflammatory agent: implications to radiothe-rapy and chemotherapy[J]. J Cell Physiol, 2019, 234(5): 5728-5740.
34	Guo JC, Xie H, Wu H, et al. Efficacy of lycopene in the treatment of oral submucous fibrosis: a meta-analysis of randomized controlled trials[J]. J Evid Based Dent Pract, 2020, 20(4): 101471.
35	Xie H, Guo JC, Tan BY, et al. Efficacy of salvia miltiorrhiza injection combined with steroids in the treatment of oral submucous fibrosis: a meta-analysis of rando-mized controlled trials[J]. Medicine (Baltimore), 2019, 98(27): e16339.
36	Guo JC, Xie H, Mao S, et al. Efficacy of hyaluronidase combined with corticosteroids in treatment of oral submucous fibrosis: a meta-analysis of randomized controlled clinical trials[J]. J Oral Pathol Med, 2020, 49(4): 311-319.

步骤	检索策略
1	“Oral submucous fibrosis”[MeSH] OR “OSF” [MeSH] OR “OSMF” [MeSH]
2	“Atrophia idiopathica mucosae oris” [Title/Abstract] OR “Diffuse oral submucous fibrosis” [Title/Abstract] OR “Submucous fibrosis of the palate and pillars” OR “Idiopathic scleroderma of the mouth” [Title/Abstract] OR “Asian side-ropenic dysphagia” [Title/Abstract] OR “Sclerosing stomatitis” [Title/Abstract] OR “Idiopathic palatal fibrosis” [Title/Abstract] OR “Juxta-epithelial fibrosis” [Title/Abstract]
3	1 OR 2
4	“Curcumin” [Title/Abstract] OR “Turmeric” [Title/Abstract]
5	3 AND 4

纳入研究	例数 (T/C)	年龄/岁		性别（男/女）		干预措施		疗程/月	随访时间/月	结局指标
纳入研究	例数 (T/C)	年龄/岁		性别（男/女）		T	C	疗程/月	随访时间/月	结局指标
Piyush 等^[16]	30/30	17~60（32）		53/7		姜黄素300 mg, po,bid	番茄红素8 mg,po, bid	6	3	①② ③④
Saran 等^[17]	30/30	T:27.9±8.66	C:26.00±6.43	T:21/9	C:19/11	姜黄素300 mg, po,tid	番茄红素4 mg,po, bid	3	1	①②
Ara 等^[18]	50/50	T:25.42±7.38	C:25.44±5.43	T:45/5	C:48/2	姜黄素500 mg, po,bid	安慰剂500 mg,po, bid	6	0	①② ③④
Kopuri 等^[19]	15/15	不详		不详		姜黄素400 mg, po,bid	番茄红素4mg,po, bid	3	0	①② ⑤⑥
Hazarey等^[20]	15/15	18~50		不详		姜黄素400 mg, po,tid	局部涂氯倍他索乳膏, tid	3	6	①②
Yadav等^[21]	20/20	T:37.9±10.5	C:37.9±10.5	T:15/5	C:16/4	姜黄素300 mg, po,qd	地塞米松4 mg+透明质酸酶1 500 IU局部注射, 1周1次	3	3	①④

纳入研究	随机方法	分配隐藏	盲法		结果数据完整性	选择性报告研究结果	其他偏倚
纳入研究	随机方法	分配隐藏	研究和受试者	结果评价者	结果数据完整性	选择性报告研究结果	其他偏倚
Piyush等^[16]	计算机随机	不透明信封	双盲	盲法	完整	低风险	不清楚
Saran等^[17]	鱼缸法	不清楚	双盲	盲法	完整	低风险	不清楚
Ara等^[18]	随机数字表法	不清楚	单盲	盲法	完整	低风险	不清楚
Kopuri等^[19]	不清楚	不清楚	不清楚	不清楚	完整	低风险	不清楚
Hazarey等^[20]	不清楚	不清楚	不清楚	不清楚	完整	低风险	不清楚
Yadav等^[21]	随机数字表法	不清楚	不清楚	不清楚	完整	低风险	不清楚

[1]	张静, 王雁. 中国学龄前儿童龋齿患病率及填充率的Meta分析[J]. 华西口腔医学杂志, 2023, 41(5): 573-581.
[2]	程小明, 唐睿, 葛自力. 比较隧道术及冠向复位瓣术治疗牙龈退缩的疗效及长期稳定性的Meta分析[J]. 华西口腔医学杂志, 2023, 41(4): 450-462.
[3]	李雨霖, 徐静晨, 蒋晓鸽, 陈嵩. Twin-block矫治器对安氏Ⅱ类错患者髁突影响的Meta分析[J]. 华西口腔医学杂志, 2023, 41(4): 463-470.
[4]	余磊, 李紫薇, 康芙嘉, 王宋庆, 谢尊玄, 朱宪春. 隐形功能矫治器对比传统功能矫治器前导下颌治疗骨性Ⅱ类错畸形患者疗效的meta分析[J]. 华西口腔医学杂志, 2023, 41(3): 305-314.
[5]	杨靖梅, 周子亮, 吴亚菲, 聂敏. 基于网络药理学和分子对接技术探究姜黄素治疗牙周炎的作用机制[J]. 华西口腔医学杂志, 2023, 41(2): 157-164.
[6]	张启航, 龚佳明, 余佳颖, 赵瑞敏, 苟萍, 余占海. 在后牙区应用4 mm超短种植体临床效果的Meta分析[J]. 华西口腔医学杂志, 2023, 41(1): 80-87.
[7]	洪飞若, 陈飘飘, 俞雪芬, 曾江. 中国成年人牙科焦虑症患病率的Meta分析[J]. 华西口腔医学杂志, 2023, 41(1): 88-98.
[8]	从兆霞, 刘媛, 赵今. 运用脱细胞真皮基质或结缔组织移植物治疗多发性相邻牙龈退缩的Meta分析[J]. 华西口腔医学杂志, 2022, 40(6): 690-697.
[9]	龚佳明, 张启航, 苟萍, 王辉, 余佳颖, 余占海. 自体牙本质用于牙槽嵴增量的Meta分析[J]. 华西口腔医学杂志, 2022, 40(5): 566-575.
[10]	殷荫, 曾维, 敬伟, 汤炜, 郭维华. 高压氧治疗放射性颌骨骨坏死效果的系统评价[J]. 华西口腔医学杂志, 2021, 39(6): 690-697.
[11]	包明哲, 刘伟, 余树容, 门乙, 韩波, 李春洁. 富血小板纤维蛋白在下颌第三磨牙拔除术的应用系统评价与Meta分析[J]. 华西口腔医学杂志, 2021, 39(5): 605-611.
[12]	陈玲, 陈成, 李志勇, 张绮. 口内扫描数字化印模对固定修复临床应用效果的Meta分析[J]. 华西口腔医学杂志, 2021, 39(3): 306-312.
[13]	柏银, 白远亮, 赖静, 黄姣. 克拉霉素辅助治疗慢性牙周炎疗效的Meta分析[J]. 华西口腔医学杂志, 2020, 38(3): 290-296.
[14]	石慧,葛红珊,陈露祎,李志华. 骨支抗装置与上颌面具前牵引装置治疗青少年骨性Ⅲ类错颌畸形疗效比较的Meta分析[J]. 华西口腔医学杂志, 2020, 38(1): 69-74.
[15]	许智,吕逢源,姜二辉,赵小平,尚政军. 槟榔与细胞内活性氧及自噬的关系[J]. 华西口腔医学杂志, 2020, 38(1): 80-85.

姜黄素治疗口腔黏膜下纤维性变有效性的Meta分析

Efficacy of curcumin in the treatment of oral submucous fibrosis: a Meta-analysis

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 8

参考文献 36

相关文章 15

编辑推荐

Metrics

本文评价